News
Novo Nordisk Wins TM Infringement Ruling on Ozempic, Wegovy Marks
A U.S. magistrate judge in Texas found that MD Exam infringed Novo Nordisk trademarks protecting the weight-loss drugs Ozempic and Wegovy. The ruling came in a case where the defendant advertised an "oral Ozempic" and "Wegovy program" without selling the actual medications or obtaining permission to use the marks.
Magistrate Judge Detra Shaw-Wilder noted that MD Exam conceded it never requested permission and used the marks to promote competing compounded semaglutide products. The decision establishes infringement based on the unauthorized use in advertising.
The case highlights ongoing enforcement efforts by brand owners against compounded versions of popular GLP-1 drugs. Novo Nordisk has pursued multiple actions to protect its marks from similar copycat marketing.
The ruling grants Novo Nordisk relief on its trademark claims while the litigation continues on other aspects. It underscores judicial scrutiny of marketing that could confuse consumers about the source or nature of compounded pharmaceuticals.
Sources: https://news.bloomberglaw.com/ip-law/novo-nordisk-proves-copycat-wegovy-ozempic-infringed-trademarks https://www.law360.com/cases/687e69c7a873adb940c42f51